"AHFS® Drug Information™ succeeds in offering an updated drug compendium of evidence-based drug monographs, meeting the needs of today's healthcare professionals. The reference continues to be trustworthy, relying on the most prestigious and knowledgeable drug experts in the medical field.
This reference can be used by any healthcare professional utilizing or prescribing medications in their practice, including physicians, pharmacists, physician assistants, and nurse practitioners. The book is so nicely organized and easily referenced that it can also be used by students in the medical, pharmacy, and nursing fields as well."
(Melissa M. Potts, BS, PharmD, Doody's Review Service, 2020)
AHFS Drug Information® 2022 - Trusted by pharmacists and other healthcare professionals for over 60 years, AHFS® DI™ is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.
AHFS : is the only drug information resource curated by a not-for-profit scientific organization and the only remaining original federal compendium whose authority for establishing accepted medical uses includes the broadest scope of drugs and indications under Medicaid, Medicare Part D, and more.
With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS® DI™ helps you protect your patients and your practice.
2022 Updates Include:
Drug information for COVID-19 vaccines and COVID-19 monoclonal antibodies available under FDA Emergency Use Authorizations (EUAs), including clinical considerations from the US Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and other authorities
- Breakthroughs in oncology approved under the FDA's accelerated approval program
Expanded content on off-label uses, real-world data, and long-term clinical data
- Information on patient selection and appropriate use of corticosteroids in the management of COVID-19 based on recent guidelines from NIH and the World Health Organization (WHO)
- Contemporary issues such as anticoagulant reversal strategies and use of direct oral anticoagulants versus warfarin for treatment of venous thromboembolism or atrial fibrillation
- Current best practices such as reversal of neuromuscular blocking agents for prevention of postoperative residual neuromuscular blockade
- Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
- Additon of 51 new molecular entities (NMEs) or new therapeutic biological products approved since January 2021
ISBN 10: 1585286842
ISBN 13: 9781585286843